Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHK1 as a therapeutic target to bypass chemoresistance in AML

13 Sept 2016

Abstract excerpt

The nucleoside analog cytarabine, an inhibitor of DNA replication fork progression that results in DNA damage, is currently used in the treatment of acute myeloid leukemia (AML). We explored the prognostic value of the expression of 72 genes involved in various aspects of DNA replication in a set of 198 AML patients treated by cytarabine-based chemotherapy. We unveiled that high expression of the DNA replication...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27625304
DOI: 10.1126/scisignal.aac9704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHK1 as a therapeutic target to bypass chemoresistance in AMLPMID 27625304Read ↗

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting TherapySemantic proximity Read ↗

Reality CHEK: Understanding the biology and clinical potential of CHK1Semantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsSemantic proximity Read ↗

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.Semantic proximity Read ↗

Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication CheckpointSemantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?Semantic proximity Read ↗

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapySemantic proximity Read ↗

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell deathSemantic proximity Read ↗

Targeting the checkpoint kinase Chk1 in cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.